Epigenic Therapeutics Co. Ltd. has closed a $60 million Series B financing round to advance clinical development of gene therapy candidates: EPI-003 for chronic hepatitis B virus (HBV) and EPI-001 for hypercholesterolemia. The company uses CRISPR-based epigenome editing approaches to modulate gene expression without altering DNA sequences, potentially offering safer and precise treatments. This funding will accelerate clinical trials in these high unmet need areas, positioning Epigenic as a pioneer in epigenetic gene therapy modalities.